PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13231543::ACT047720

sP10

Evidence text

Paper-level observation

In vitro experiments confirmed that the IC50 of sP10-LNP on hepatoma cells decreased from 18.71 µM to 9.568 µM (with a 49% increase in activity) (Fig. 7E).
textConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Not reported by source
Measure
other
Comparator
=
Raw observation
9.568 µM
Normalized measurement
=9.568 µM
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
SK-Hep1
Assay method
Not reported by source
Sequence
YGRKKRRQRRRCGPVWFLIFSYFLFFSISLARGPC
Standardization
ready simple

Source publication

Peptide aptamer sP10 targeting NPM1 attenuates liver fibrosis and hepatocellular carcinoma.

Journal of Translational Medicine · 2026

DOI 10.1186/s12967-026-08144-8 PMC13231543
Parent mention

Related peptide identities

PEPDIA-PLP-003251

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.